Cannara Historical Financial Ratios

LOVE Stock  CAD 0.70  0.02  2.78%   
Cannara Biotech is presently reporting on over 80 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 55.3 will help investors to properly organize and evaluate Cannara Biotech financial condition quickly.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Cannara Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

About Cannara Financial Ratios Analysis

Cannara BiotechFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Cannara Biotech investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Cannara financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Cannara Biotech history.

Cannara Biotech Financial Ratios Chart

At this time, Cannara Biotech's Capex To Operating Cash Flow is fairly stable compared to the past year. PFCF Ratio is likely to climb to 20.01 in 2024, whereas PTB Ratio is likely to drop 0.66 in 2024.
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Cannara Biotech stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cannara Biotech sales, a figure that is much harder to manipulate than other Cannara Biotech multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Stock Based Compensation To Revenue

A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.
Most ratios from Cannara Biotech's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Cannara Biotech current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Cannara Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
At this time, Cannara Biotech's Capex To Operating Cash Flow is fairly stable compared to the past year. PFCF Ratio is likely to climb to 20.01 in 2024, whereas PTB Ratio is likely to drop 0.66 in 2024.
 2022 2023 2024 (projected)
Days Sales Outstanding67.5258.2155.3
PTB Ratio1.120.70.66

Cannara Biotech fundamentals Correlations

1.01.0-0.940.25-0.13-0.741.01.01.0-0.2-0.37-0.93-0.11-0.97-0.66-0.741.00.4-0.98-0.64-0.82-0.60.37-0.03-0.44
1.01.0-0.940.22-0.15-0.740.991.01.0-0.23-0.38-0.93-0.11-0.97-0.68-0.750.990.4-0.99-0.64-0.84-0.620.36-0.05-0.43
1.01.0-0.930.24-0.13-0.731.01.01.0-0.22-0.36-0.9-0.1-0.98-0.67-0.741.00.44-0.98-0.63-0.82-0.610.4-0.06-0.42
-0.94-0.94-0.93-0.160.230.83-0.93-0.94-0.940.210.490.910.230.90.670.75-0.94-0.40.910.730.740.52-0.370.040.55
0.250.220.24-0.160.890.20.210.220.250.850.64-0.340.78-0.360.550.440.19-0.42-0.160.380.090.28-0.390.340.57
-0.13-0.15-0.130.230.890.42-0.16-0.15-0.120.840.850.010.86-0.010.790.69-0.18-0.590.170.680.270.48-0.540.490.8
-0.74-0.74-0.730.830.20.42-0.77-0.74-0.740.550.690.610.580.710.780.87-0.78-0.650.760.820.760.42-0.66-0.190.75
1.00.991.0-0.930.21-0.16-0.770.990.99-0.25-0.4-0.89-0.15-0.98-0.69-0.771.00.48-0.98-0.66-0.83-0.610.44-0.03-0.46
1.01.01.0-0.940.22-0.15-0.740.991.0-0.23-0.38-0.93-0.11-0.97-0.68-0.750.990.4-0.99-0.64-0.84-0.620.36-0.05-0.43
1.01.01.0-0.940.25-0.12-0.740.991.0-0.19-0.37-0.93-0.1-0.97-0.66-0.730.990.4-0.98-0.64-0.82-0.60.36-0.03-0.43
-0.2-0.23-0.220.210.850.840.55-0.25-0.23-0.190.670.030.740.120.810.77-0.26-0.660.310.560.550.48-0.60.290.65
-0.37-0.38-0.360.490.640.850.69-0.4-0.38-0.370.670.230.950.240.820.8-0.44-0.660.370.940.350.42-0.690.090.99
-0.93-0.93-0.90.91-0.340.010.61-0.89-0.93-0.930.030.23-0.070.870.520.57-0.89-0.060.920.50.770.55-0.020.020.28
-0.11-0.11-0.10.230.780.860.58-0.15-0.11-0.10.740.95-0.070.00.710.68-0.18-0.670.120.810.20.25-0.710.040.93
-0.97-0.97-0.980.9-0.36-0.010.71-0.98-0.97-0.970.120.240.870.00.550.66-0.97-0.440.950.530.790.49-0.4-0.010.32
-0.66-0.68-0.670.670.550.790.78-0.69-0.68-0.660.810.820.520.710.550.96-0.71-0.680.710.860.740.76-0.640.260.83
-0.74-0.75-0.740.750.440.690.87-0.77-0.75-0.730.770.80.570.680.660.96-0.78-0.720.790.870.820.59-0.670.160.82
1.00.991.0-0.940.19-0.18-0.781.00.990.99-0.26-0.44-0.89-0.18-0.97-0.71-0.780.49-0.98-0.69-0.83-0.610.46-0.03-0.5
0.40.40.44-0.4-0.42-0.59-0.650.480.40.4-0.66-0.66-0.06-0.67-0.44-0.68-0.720.49-0.39-0.66-0.38-0.320.97-0.19-0.68
-0.98-0.99-0.980.91-0.160.170.76-0.98-0.99-0.980.310.370.920.120.950.710.79-0.98-0.390.620.910.61-0.340.050.43
-0.64-0.64-0.630.730.380.680.82-0.66-0.64-0.640.560.940.50.810.530.860.87-0.69-0.660.620.540.51-0.69-0.010.97
-0.82-0.84-0.820.740.090.270.76-0.83-0.84-0.820.550.350.770.20.790.740.82-0.83-0.380.910.540.57-0.30.010.41
-0.6-0.62-0.610.520.280.480.42-0.61-0.62-0.60.480.420.550.250.490.760.59-0.61-0.320.610.510.57-0.320.350.4
0.370.360.4-0.37-0.39-0.54-0.660.440.360.36-0.6-0.69-0.02-0.71-0.4-0.64-0.670.460.97-0.34-0.69-0.3-0.32-0.02-0.71
-0.03-0.05-0.060.040.340.49-0.19-0.03-0.05-0.030.290.090.020.04-0.010.260.16-0.03-0.190.05-0.010.010.35-0.020.01
-0.44-0.43-0.420.550.570.80.75-0.46-0.43-0.430.650.990.280.930.320.830.82-0.5-0.680.430.970.410.4-0.710.01
Click cells to compare fundamentals

Cannara Biotech Account Relationship Matchups

Cannara Biotech fundamentals Accounts

201920202021202220232024 (projected)
Price To Sales Ratio26.577.643.31.560.750.71
Ptb Ratio2.321.772.031.120.70.66
Days Sales Outstanding44.1763.6587.7667.5258.2155.3
Book Value Per Share0.540.840.760.890.980.56
Operating Cash Flow Per Share(0.1)(0.13)(0.0274)(0.0693)0.06090.12
Stock Based Compensation To Revenue0.310.01950.009750.03060.02420.023
Capex To Depreciation3.4110.273.952.01.181.12
Pb Ratio2.321.772.031.120.70.66
Ev To Sales28.598.394.312.281.261.2
Free Cash Flow Per Share(0.42)(0.25)(0.43)(0.0497)0.03570.0375
Roic(0.18)(0.25)0.0046110.03960.09480.11
Inventory Turnover0.590.910.980.891.30.7
Net Income Per Share(0.19)(0.0404)0.02630.07780.07150.0751
Days Of Inventory On Hand616.86402.27374.25410.49281.49201.94
Payables Turnover0.481.092.173.385.285.54
Sales General And Administrative To Revenue3.160.360.240.190.160.15
Capex To Revenue3.461.830.430.170.09140.0868
Pocfratio(7.27)(62.15)(19.47)16.425.736.02
Interest Coverage(9.0)0.121.912.242.332.45
Capex To Operating Cash Flow(0.95)(14.85)(2.54)1.820.70.73
Pfcf Ratio(3.74)(3.92)(5.49)(20.1)19.0620.01
Days Payables Outstanding758.16336.1168.28108.069.1465.68
Income Quality0.711.37(2.64)0.781.661.74
Roe(0.36)(0.0483)0.03450.08710.07320.0769
Ev To Operating Cash Flow(7.82)(68.24)(25.44)24.069.6410.12
Pe Ratio(4.91)(42.04)51.3412.869.519.99
Return On Tangible Assets(0.25)(0.0336)0.01840.04910.04160.0437
Ev To Free Cash Flow(4.02)(4.31)(7.18)(29.45)32.0333.63
Earnings Yield(0.13)(0.2)(0.0238)0.01950.07780.11
Net Debt To E B I T D A(0.56)3.953.82.632.751.57
Current Ratio3.032.823.462.442.54.92
Tangible Book Value Per Share0.540.840.760.890.980.56
Receivables Turnover8.265.734.165.416.273.78
Graham Number1.711.530.870.671.250.88
Shareholders Equity Per Share0.540.840.760.890.980.56

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Cannara Stock Analysis

When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.